{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:14:35Z","timestamp":1792602875274,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003091","name":"key research and development project of Shandong Province","doi-asserted-by":"publisher","award":["2017CXGC1401"],"award-info":[{"award-number":["2017CXGC1401"]}],"id":[{"id":"10.13039\/501100003091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.bioorg.2019.102943","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T09:31:55Z","timestamp":1556184715000},"page":"102943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL"],"prefix":"10.1016","volume":"89","author":[{"given":"Fansheng","family":"Ran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junze","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2019.102943_b0005","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23176","article-title":"Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management","volume":"87","author":"Vose","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bioorg.2019.102943_b0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1440-1827.1997.tb04519.x","article-title":"Cyclin D1 overexpression in malignant lymphomas","volume":"47","author":"Nakamura","year":"1997","journal-title":"Pathol. Int."},{"key":"10.1016\/j.bioorg.2019.102943_b0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2019.102943_b0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2017.06.067","article-title":"Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity","volume":"138","author":"Liu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.102943_b0025","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2019.102943_b0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2019.102943_b0035","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient Expression of a B-Cell Cytoplasmic Tyrosine Kinase in Human X-Linked Agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2019.102943_b0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0952-7915(00)00221-1","article-title":"Tec kinases: modulators of lymphocyte signaling and development","volume":"13","author":"Lewis","year":"2001","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bioorg.2019.102943_b0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","author":"Kuppers","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2019.102943_b0050","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1073\/pnas.91.22.10606","article-title":"Bruton tyrosine kinase is tyrosine-phosphorylated and activated in Pre-B lymphocytes and receptor-ligated B-cells","volume":"91","author":"Aoki","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2019.102943_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1074-7613(00)80153-3","article-title":"BLNK: Connecting Syk and Btk to calcium signals","volume":"12","author":"Kurosaki","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2019.102943_b0060","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nri1591","article-title":"TEC-family kinases: Regulators of T-helper-cell differentiation","volume":"5","author":"Schwartzberg","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2019.102943_b0065","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201700369","article-title":"Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors","volume":"351","author":"Zhang","year":"2018","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2019.102943_b0070","first-page":"161","article-title":"Novel Bruton's tyrosine kinase inhibitors currently in development","volume":"6","author":"D'Cruz","year":"2013","journal-title":"Oncotargets Ther."},{"key":"10.1016\/j.bioorg.2019.102943_b0075","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2019.102943_b0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.bioorg.2019.102943_b0085","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2019.102943_b0090","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leukemia Res."},{"key":"10.1016\/j.bioorg.2019.102943_b0095","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"issue":"59","key":"10.1016\/j.bioorg.2019.102943_b0100","article-title":"Ibrutinib and novel BTK inhibitors in clinical development","volume":"6","author":"Akinleye","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2019.102943_b0105","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.bioorg.2019.102943_b0110","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40266-017-0468-4","article-title":"Current status of Bruton\u2019s tyrosine kinase inhibitor development and use in B-cell malignancies","volume":"34","author":"Aw","year":"2017","journal-title":"Drugs Aging."},{"key":"10.1016\/j.bioorg.2019.102943_b0115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"Chemmedchem"},{"key":"10.1016\/j.bioorg.2019.102943_b0120","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting BTK with Ibrutinib in Relapsed\/ Refractory Marginal Zone Lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2019.102943_b0125","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.2174\/0929867325666180316121951","article-title":"Development of Bruton's tyrosine kinase Inhibitors for Rheumatoid Arthritis","volume":"25","author":"Lv","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.102943_b0130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2018.03.062","article-title":"The development of Bruton's tyrosine kinase (BTK) inhibitors from, 2012 to 2017: A mini-review","volume":"151","author":"Liang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.102943_b0135","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","author":"Walter","year":"2016","journal-title":"Blood 127"},{"key":"10.1016\/j.bioorg.2019.102943_b0140","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.113.203489","article-title":"Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans","author":"Evans","year":"2013","journal-title":"J. Pharmacol. Exp. Ther. 346"},{"key":"10.1016\/j.bioorg.2019.102943_b0145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13075-016-0988-z","article-title":"HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bioorg.2019.102943_b0150","doi-asserted-by":"crossref","first-page":"15122","DOI":"10.18632\/oncotarget.3824","article-title":"Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma","volume":"6","author":"Ding","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2019.102943_b0155","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1021\/acsmedchemlett.5b00463","article-title":"Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis","volume":"7","author":"Liu","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.102943_b0160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bmcl.2017.11.037","article-title":"Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors","volume":"28","author":"Kawahata","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.102943_b0165","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bmcl.2015.11.076","article-title":"Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability","volume":"26","author":"Young","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.102943_b0170","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.bmcl.2015.01.032","article-title":"Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834","volume":"25","author":"Young","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2019.102943_b0175","doi-asserted-by":"crossref","first-page":"9625","DOI":"10.1021\/acs.jmedchem.5b01611","article-title":"Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia","volume":"58","author":"Li","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2019.102943_b0180","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1021\/acs.jmedchem.8b00095","article-title":"Discovery of Inhibitor of Wnt Production 2 (IWP-2) and Related Compounds As Selective ATP-Competitive Inhibitors of Casein Kinase 1 (CK1) delta\/epsilon","volume":"61","author":"Garcia-Reyes","year":"2018","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206818314378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206818314378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T03:45:50Z","timestamp":1569123950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206818314378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":36,"alternative-id":["S0045206818314378"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2019.102943","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2019.102943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102943"}}